Answers are grounded in this paper and cite their sources.
Translational review reveals clinical translation strategies for mesenchymal stem cell-derived extracellular vesicles in spinal cord injury, indicating pathways toward human trials.
A large body of animal studies across multiple laboratories has found that a subset of small extracellular vesicles (sEVs) derived from mesenchymal stromal cells (MSC-sEVs) referred to as exosomes can improve functional recovery after spinal cord injury (SCI). Sufficient pre-clinical data have been accumulated to consider how MSC-sEVs might be used clinically for the treatment of SCI. This review discusses: (1) the SCI patient population which may benefit from MSC-sEVs treatments, (2) potential sources of MSCs for production of clinically useful MSC-sEVs, (3) dosaging of MSC-sEVs required for therapeutic efficacy, (4) timing and method of delivery of the sEVs, (5) cell targets of MSC-sEVs and their mechanism of action, (6) possible protocols for producing clinically useful quantities of MSC-sEVs, and (7) the criteria for evaluating an MSC-sEVs treatment product. We conclude with some thoughts about potential protocols for clinical trials of MSC-sEVs treatment for SCI.
No takes yet. Share an insight, caveat, or question.
Lankford et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: